Neurofibromatosis: genes and variants
Explore variant evidence for Neurofibromatosis across 4 analyzed proteins (NF1, NF2, MAP2K1, MAP2K2). Linked ClinVar records include 57 pathogenic or likely pathogenic variants, 1,336 variants of uncertain significance and 131 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Neurofibromatosis
NF1: Neurofibromin
It accelerates conversion of active RAS-GTP to inactive RAS-GDP and therefore restrains RAS-MAPK signaling. Loss-of-function variants cause neurofibromatosis type 1 with neurofibromas, pigmentary features, learning difficulties, and increased tumor risk.
51 ClinVar pathogenic / likely pathogenic and 854 uncertain variants in NF1 have source records linked to Neurofibromatosis. Association strength is not clinical gene validity.
NF2: Merlin
Its merlin product links membrane and cytoskeletal signaling to contact-dependent growth control. Germline loss-of-function variants cause NF2-related schwannomatosis with vestibular schwannomas, meningiomas, and other nervous-system tumors.
6 ClinVar pathogenic / likely pathogenic and 611 uncertain variants in NF2 have source records linked to Neurofibromatosis. Association strength is not clinical gene validity.
MAP2K1: Dual specificity mitogen-activated protein kinase kinase 1
It phosphorylates ERK1 and ERK2 downstream of RAF and thereby propagates RAS-MAPK growth and developmental signals. Activating somatic variants occur in several cancers, while germline activating variants can cause cardio-facio-cutaneous syndrome and related RASopathies.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K1 have source records linked to Neurofibromatosis. Association strength is not clinical gene validity.
MAP2K2: Dual specificity mitogen-activated protein kinase kinase 2
It works with MEK1 to activate ERK signaling downstream of RAS and RAF. Germline activating variants can cause cardio-facio-cutaneous syndrome, while acquired activation can support oncogenic MAPK signaling and drug resistance.
0 ClinVar pathogenic / likely pathogenic and 0 uncertain variants in MAP2K2 have source records linked to Neurofibromatosis. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): ARID1B and NOTCH1.
ClinVar pathogenic and likely pathogenic variants linked to Neurofibromatosis
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| NF2 L64P | 64 | FERM | Pathogenic / likely pathogenic (★★) |
| NF2 N220Y | 220 | FERM | Pathogenic / likely pathogenic (★★) |
| NF2 L517P | 517 | Pathogenic / likely pathogenic (★★) | |
| NF1 M1I | 1 | Pathogenic / likely pathogenic (★★) | |
| NF1 T59P | 59 | Pathogenic / likely pathogenic (★★) | |
| NF1 I177K | 177 | Pathogenic / likely pathogenic (★★) | |
| NF1 Q270P | 270 | Pathogenic / likely pathogenic (★★) | |
| NF1 K395N | 395 | Pathogenic / likely pathogenic (★★) | |
| NF1 L549R | 549 | Pathogenic / likely pathogenic (★★) | |
| NF1 S574T | 574 | Pathogenic / likely pathogenic (★★) | |
| NF1 V917G | 917 | Pathogenic / likely pathogenic (★★) | |
| NF1 A1071P | 1071 | Pathogenic / likely pathogenic (★★) | |
| NF1 L1104R | 1104 | Pathogenic / likely pathogenic (★★) | |
| NF1 N1683K | 1683 | CRAL-TRIO | Pathogenic / likely pathogenic (★★) |
| NF1 G2397W | 2397 | Pathogenic / likely pathogenic (★★) | |
| NF1 R1412T | 1412 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 N1451K | 1451 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 S2018I | 2018 | Pathogenic / likely pathogenic (★) | |
| NF1 D1217Y | 1217 | Pathogenic / likely pathogenic (★) | |
| NF1 D1217N | 1217 | Pathogenic / likely pathogenic (★) | |
| NF1 R1412K | 1412 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 M1461I | 1461 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 S2018R | 2018 | Pathogenic / likely pathogenic (★) | |
| NF1 N1154T | 1154 | Pathogenic / likely pathogenic (★) | |
| NF1 L43R | 43 | Pathogenic / likely pathogenic (★) | |
| NF1 S47F | 47 | Pathogenic / likely pathogenic (★) | |
| NF1 V54D | 54 | Pathogenic / likely pathogenic (★) | |
| NF1 I117N | 117 | Pathogenic / likely pathogenic (★) | |
| NF1 L145P | 145 | Pathogenic / likely pathogenic (★) | |
| NF1 D338N | 338 | Pathogenic / likely pathogenic (★) | |
| NF1 A545E | 545 | Pathogenic / likely pathogenic (★) | |
| NF1 M577R | 577 | Pathogenic / likely pathogenic (★) | |
| NF1 W784G | 784 | Pathogenic / likely pathogenic (★) | |
| NF1 R1000S | 1000 | Pathogenic / likely pathogenic (★) | |
| NF1 N1156H | 1156 | Pathogenic / likely pathogenic (★) | |
| NF1 T1191P | 1191 | Pathogenic / likely pathogenic (★) | |
| NF1 T1199P | 1199 | Pathogenic / likely pathogenic (★) | |
| NF1 G1277R | 1277 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 S1279R | 1279 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 L1446R | 1446 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 E1458D | 1458 | Ras-GAP | Pathogenic / likely pathogenic (★) |
| NF1 F1536V | 1536 | Pathogenic / likely pathogenic (★) | |
| NF1 A1610E | 1610 | CRAL-TRIO | Pathogenic / likely pathogenic (★) |
| NF1 D1644V | 1644 | CRAL-TRIO | Pathogenic / likely pathogenic (★) |
| NF1 T1646P | 1646 | CRAL-TRIO | Pathogenic / likely pathogenic (★) |
| NF1 D1849Y | 1849 | Pathogenic / likely pathogenic (★) | |
| NF1 S1912R | 1912 | Pathogenic / likely pathogenic (★) | |
| NF1 L1915R | 1915 | Pathogenic / likely pathogenic (★) | |
| NF1 L1953V | 1953 | Pathogenic / likely pathogenic (★) | |
| NF1 L1978P | 1978 | Pathogenic / likely pathogenic (★) | |
| NF1 L2133V | 2133 | Pathogenic / likely pathogenic (★) | |
| NF1 K2273T | 2273 | Pathogenic / likely pathogenic (★) | |
| NF1 L2337P | 2337 | Pathogenic / likely pathogenic (★) | |
| NF1 T2409R | 2409 | Pathogenic / likely pathogenic (★) | |
| NF2 L360P | 360 | Pathogenic / likely pathogenic | |
| NF2 L535P | 535 | Pathogenic / likely pathogenic | |
| NF2 Q538P | 538 | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Neurofibromatosis
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| NF1 G1277D | 1277 | Ras-GAP | Uncertain (★★) | +6: 2 other pathogenic changes within 3 positions; G1277R at the same position is pathogenic; seen in 6.6e-06 of gnomAD DNA copies; REVEL 0.760 |
Which prediction tools work for Neurofibromatosis
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- AlphaMissense: 97 out of 100
- ESM1b (LLR): 90 out of 100
- CATVariant: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaLR: 89 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 84 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- SIFT: 83 out of 100
- MutPred: 81 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 77 out of 100
- PolyPhen-2: 75 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Neurofibromatosis
- Melanoma, also linked to MAP2K1, MAP2K2 and NF1
- Hypertrophic cardiomyopathy, also linked to MAP2K1 and MAP2K2
- RASopathy, also linked to MAP2K1 and MAP2K2
- Noonan syndrome, also linked to MAP2K1 and MAP2K2
- Noonan syndrome and Noonan-related syndrome, also linked to MAP2K1 and MAP2K2
- Cardiofaciocutaneous syndrome, also linked to MAP2K1 and MAP2K2
- Cardio-facio-cutaneous syndrome, also linked to MAP2K1 and MAP2K2
- Costello syndrome, also linked to MAP2K1 and MAP2K2
- Urinary bladder cancer, also linked to NF1
- Non-small cell lung carcinoma, also linked to MAP2K1
- Vascular malformation, also linked to MAP2K1
- Myelomonocytic leukemia, also linked to NF1
Frequently asked questions
Which genes have records linked to Neurofibromatosis?
This view contains 4 analyzed proteins: NF1, NF2, MAP2K1, MAP2K2. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 57 pathogenic or likely pathogenic variants, 1,336 variants of uncertain significance and 131 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 1,637 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center